---
document_datetime: 2023-09-21 20:57:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ngenla-epar-all-authorised-presentations_en.pdf
document_name: ngenla-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7444499
conversion_datetime: 2025-12-25 12:03:59.607351
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength      | Pharmaceutical Form    | Route of Administration   | Immediate Packaging                   | Content (concentration)   | Pack size        |
|------------------|-------------------|---------------|------------------------|---------------------------|---------------------------------------|---------------------------|------------------|
| EU/1/21/1617/001 | NGENLA            | 24 mg/ 1.2 ml | Solution for injection | Subcutaneous use          | cartridge (glass) in a pre-filled pen | 1.2 ml (20 mg/ml)         | 1 pre-filled pen |
| EU/1/21/1617/002 | NGENLA            | 60 mg/ 1.2 ml | Solution for injection | Subcutaneous use          | cartridge (glass) in a pre-filled pen | 1.2 ml (50 mg/ml)         | 1 pre-filled pen |